Novartis
NEWS
Alcon, the Novartis eye care business, is leaving its longtime home of Texas for Switzerland. The company said it will move its corporate headquarters from Fort Worth to Geneva following the spinoff from Novartis.
Let’s take a look at who made a splash in the pharma and biotech world the past week.
Today Narasimhan and Novartis announced they were selling U.S. dermatology and generic drug assets, parts of its Sandoz division, to India’s Aurobindo Pharma for up to $1 billion. The deal includes approximately 300 products.
Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS).
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Maryland-based REGENXBIO is expanding its gene therapy pipeline to include a new treatment for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease.
The United Kingdom’s government-funded health service isn’t being so nice to Gilead Science’s CAR-T blood cancer treatment Yescarta. The country’s National Institute for Health and Care Excellence (NICE) said the therapy is too expensive for the agency to justify.
Who made a splash in the biotech world this week? Here are some notable people.
Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs that has a troubling history of adverse events.
JOBS
IN THE PRESS